Docetaxel-Ifosfamide Combination in Patients with Advanced Breast Cancer Failing Prior Anthracycline- Based Regimens: Results of a Phase I-II Study

References

• Salminen E, Bergman M, Huhtala S, Ekholm E. Docetaxel: standard recommended dose of 100 mg/m2 is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy-A phase II sin-gle-center study. J Clin Oncol 1999; 17: 1127-31.
   Google Scholar
• Nabholtz JM, Senn HJ, Bezwoda WR, et al, for the 304 Study Group. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 1999; 17: 1413–24.
   Google Scholar
• Sjostrom J, Blomqvist C, Mouridsen H, et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline fail-ure: a randomised phase III study with cross over on progres-sion by the Scandinavian Breast Group. Eur J Cancer 1999; 35: 1194-201.
   Google Scholar
• Monnier A, Bonneterre J, Roche H, et al. Phase III study: Taxotere (TXT) versus 5-Fluorouracil + navelbine (FUN) in patients (pts) with metastatic breast cancer (MBC) as 2nd line chemotherapy. Ann Oncol 1998; 9 (Suppl 4): 12 (abstr 580).
   Google Scholar
• Chan S, Friedrichs K, Noel D, et al. Prospective ran-domized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group. J Clin Oncol 1999; 17: 2341–54.
   PubMed Web of Science ®Google Scholar
• Paridaens R, Biganzoli L, Bruning P, et al. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol 2000; 18: 724–33.
   PubMed Web of Science ®Google Scholar
• Sledge GW Jr, Neuberg D, Ingle J, Martino S, Wood W. Phase III trial of doxorubicin (A) vs. paclitaxel (T) vs. doxoru-bicin+paclitaxel (A+T) as first-line therapy for metastatic breast cancer (MBC): an intergroup trial. Proc Am Soc Clin Oncol 1997; 16: la (abstr 2).
   Google Scholar
• Ahmann DI, Bisel HF, Hahn RG. Phase II clinical trial of isophosphamide (NSC-109724) in patients with advanced breast cancer. Cancer Chemother Rep 1974; 58: 861–5.
   PubMedGoogle Scholar
• Bitran JD, Samuels BL, Marsik S, Gambino A, White L. A phase I study of ifosfamide and doxorubicin with recombi-nant human granulocyte colony-stimulating factor in stage IV breast cancer. Clin Cancer Res 1995; 1: 185–8.
   PubMed Web of Science ®Google Scholar
• Bunnell CA, Thompson L, Buswell L, et al. A Phase I trial of ifosfamide and paclitaxel with granulocyte-colony stim-ulating factor in the treatment of patients with refractory solid tumors. Cancer 1998; 82: 561–6.
   PubMed Web of Science ®Google Scholar
• Leone BA, Vallejo CT, Romero AO, et al. Ifosfamide and vinorelbine as first-line chemotherapy for metastatic breast cancer. J Clin Oncol 1996: 11: 2993–9.
   Google Scholar
• Pronk LC, Schrijvers D, Schellens JH, et al. Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours. Br J Cancer 1998; 77: 153–8.
   PubMed Web of Science ®Google Scholar
• Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207–14.
   PubMed Web of Science ®Google Scholar
• Simon R. Confidence interval for reporting results of clinical trials. Ann Intern Med 1986; 105: 429–35.
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1959; 53: 457–81.
   Web of Science ®Google Scholar
• Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1–10.
   PubMedGoogle Scholar
• Reed E, Kohn EC, Sarosy G, et al. Paclitaxel, cisplatin, and cyclophosphamide in human ovarian cancer: molecular rationale and early clinical results. Semin Oncol 1995; 22 (Suppl. 6): 90-6.
   Google Scholar
• Klaassen U, Harstrick A, Schleucher N, et al. Activity and schedule-dependent interactions of paclitaxel, etoposide and hydroperoxy-ifosfamide in cisplatin-sensitive and -refracto-ry human ovarian carcinoma cell lines. Br J Cancer 1996; 74: 224–8.
   PubMed Web of Science ®Google Scholar
• Liebmann JE, Fisher J, Teague D. Sequence depen-dence of paclitaxel (Taxol) combined with cisplatin or alkyla-tors in human cancer cells. Oncol Res 1994; 6: 25–31.
   PubMed Web of Science ®Google Scholar
• Kearns CM, Gianni L, Egorin MJ. Paclitaxel pharmaco-kinetics and pharmacodynamics. Semin Oncol 1995; 22 (Suppl. 6): 16-23.
   Google Scholar
• Kosmas C, Tsavaris N, Polyzos A, Malamos NA, Katsikas M, Antonopoulos MJ. Phase I study of dose escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours. Br J Cancer 2000; 82: 300–7.
   PubMed Web of Science ®Google Scholar
• Kosmas C, Tsavaris N, Polyzos A, et al. A phase II study of paclitaxel-ifosfamide-cisplatin (PIC) combination in advanced non-small cell lung cancer. Cancer 2000; 89: 774–82.
   PubMed Web of Science ®Google Scholar
• Kosmas C, Tsavaris NB, Malamos NA, Vadiaka M, Koufos C. A phase II study of paclitaxel-ifosfamide-cisplatin (PIC) as second-line treatment in relapsed small-cell lung can-cer. J Clin Oncol 2001; 19: 119–26.
   PubMed Web of Science ®Google Scholar
• Kosmas C, Tsavaris N, Onyenadum A, et al. A phase I-II study of docetaxel-ifosfamide-cisplatin (DIP) combination chemotherapy regimen in advanced non-small cell lung can-cer. Int J Cancer 2002; 98: 141–147.
   PubMed Web of Science ®Google Scholar
• Kennedy MJ, Zahurak ML, Donehower RC, et al. Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony-stimu-lating factor in women with previously treated metastatic breast cancer. J Clin Oncol 1996; 14: 783–91.
   PubMed Web of Science ®Google Scholar
• Tolcher AW, Cowan KH, Noone MH, et al. Phase I study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating factor in metastatic breast can-cer patients. J Clin Oncol 1996; 14: 95–102.
   PubMed Web of Science ®Google Scholar
• Pagani 0, Sessa C, Martinelli G, et al. Dose-finding study of paclitaxel and cyclophosphamide in advanced breast cancer. Ann Oncol 1997; 8: 655–61.
   Google Scholar
• Schrijvers D, Pronk L, Highley M, et al. Pharmacokinetics of ifosfamide are changed by combination with docetaxel: results of a phase I pharmacologic study. Am J Clin Oncol 2000; 23: 358–63.
   PubMed Web of Science ®Google Scholar
• Cerny T, Leyvraz S, von Briel T, et al. Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: a pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 1999; 10: 1087–94.
   Google Scholar
• Lorusso V, Crucitta E, Sambiasi D, Attolico M, De Lena M. Docetaxel plus ifosfamide in advanced breast cancer refractory to anthracyclines: a phase II study. Ann Oncol 2000; 11 (Suppl 4): 36 (abstract 154).
   Google Scholar
• Ravdin PM, Burris HA 3rd, Cook G, et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracene-dione-resistant breast cancer. J Clin Oncol 1995; 13: 2879–85.
   PubMed Web of Science ®Google Scholar
• Valero V, Holmes FA, Walters RS, et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995; 13: 2886–94.
   PubMed Web of Science ®Google Scholar